Skip to main content
    Kriv AI

    Life Sciences & Pharma Governance

    Part 11 Compliance for AI Systems: What the Rule Requires

    What FDA's new AI credibility framework means for 21 CFR Part 11 validation work, and how the two standards fit together.

    Part 11 compliance means meeting 21 CFR Part 11, the FDA rule on electronic records and electronic signatures. Among other things it asks for validated systems, secure time-stamped audit trails and signatures linked to their records. FDA's January 2025 guidance on AI for drug and biologic submissions is a draft, not for implementation, and contains non-binding recommendations.

    context

    Part 11 compliance: what does it require?

    Part 11 compliance means a company that keeps FDA-regulated records electronically can show that those records are trustworthy. The rule is 21 CFR Part 11. Among other things, it asks for validation of systems to ensure accuracy, reliability and consistent intended performance (section 11.10(a)), secure, computer-generated, time-stamped audit trails (11.10(e)), and the ability to generate accurate and complete copies of records in human readable and electronic form (11.10(b)). For signatures, signed records must show the signer's printed name, the date and time of signing and the meaning of the signature (11.50(a)), signatures must be linked to their records (11.70), and each electronic signature must be unique to one individual (11.100(a)). The eCFR text is the rule itself. This page explains it and is not legal advice.

    Scope: electronic records and signatures

    Part 11 applies to records in electronic form that are created, modified, maintained, archived, retrieved, or transmitted under FDA recordkeeping requirements, and to electronic records submitted to the agency under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act. In practice, that covers electronic data capture systems, laboratory information management systems, electronic trial master files, and any system generating data that supports a regulatory submission.

    Validation is the load-bearing requirement

    The regulation requires that systems be validated to ensure accuracy, reliability, and consistent intended performance, along with secure, computer-generated, time-stamped audit trails and the ability to generate accurate copies of records for inspection. A system that cannot produce an audit trail on demand may not meet Part 11 where the rule for that record calls for one, regardless of how good its output looks.

    context

    CFR Part 11 compliance: what does the regulation cover and how does FDA apply it?

    CFR Part 11 compliance refers to 21 CFR Part 11, which is Part 11 of Title 21 of the Code of Federal Regulations. It sets the criteria under which FDA considers electronic records and electronic signatures trustworthy and reliable (section 11.1). In its September 2003 final guidance, Part 11, Electronic Records; Electronic Signatures, Scope and Application, FDA said it intends to interpret the scope of Part 11 narrowly. It also described enforcement discretion for specific Part 11 requirements on validation, audit trails, record retention and copies of records, and said that predicate rules still apply. FDA's page for that guidance shows content current as of 24 August 2018. Which controls apply to a given system therefore depends on the underlying FDA rule for that record, a question for your quality and regulatory team.

    ai gap

    Where AI Systems Complicate Part 11 Compliance

    Part 11's validation model assumes a deterministic system: the same input produces the same output, so validation means proving the system does that reliably. Most AI and machine learning models, including the large language models now used to draft study reports, triage adverse event narratives, or support regulatory submissions, do not behave that way. The same prompt can produce different phrasing on different runs, which is exactly the property traditional computer-system validation was not built to evaluate. For a practical example with a drafting assistant, see our guide to Copilot-generated lab records under 21 CFR Part 11.

    That gap does not exempt AI systems from Part 11. If an AI tool touches a GxP record, whatever it outputs still has to be traceable, auditable, and reproducible enough to defend in an inspection. What changes is the validation method, not the requirement.

    fda framework

    FDA's Risk-Based AI Credibility Framework

    On January 6, 2025, FDA published draft guidance, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products, proposing a risk-based credibility assessment framework for AI models used to generate information supporting drug and biologic submissions. Our guide to the FDA AI model credibility framework for drug submissions walks through the seven steps. The framework is built around a model's context of use, the specific role the AI plays and the decision it informs, and calibrates how much validation evidence that context demands.

    The guidance does not cover AI used in drug discovery or internal operational efficiency, since those uses do not directly affect participant safety or submission integrity; it is scoped to AI that supports establishing safety, effectiveness, or quality.

    engagement

    What an AI Validation Engagement Includes

    The work starts with an inventory: every AI or ML system touching GxP data or a regulatory submission, mapped to its context of use and assigned a risk tier under FDA's framework. A model summarizing internal meeting notes sits in a different tier than one drafting language for a submission dossier.

    Validation then follows a risk-based structure adapted for AI, in the spirit of the GAMP 5 computerized-system validation methodology already familiar to GxP quality teams: instead of a single deterministic test script, it uses structured output sampling against a scoring rubric, documented review of a statistically meaningful sample of outputs, and drift monitoring over time, all captured in an audit trail that satisfies Part 11's record-integrity requirement. For AI tools used in medical device production or the quality system, see the FDA computer software assurance (CSA) guidance.

    The deliverable is a validation package a sponsor can hand to an FDA inspector or a quality auditor: the risk assessment, the credibility evidence gathered, the validation protocol, and the ongoing monitoring plan, not a one-time slide deck.

    tiers

    What You Get at Each Tier

    1. 1. Enterprise / regulated (life sciences, pharma, medical device)

      A full AI validation program: system inventory, context-of-use risk tiering under FDA's framework, a validation protocol adapted for non-deterministic AI output, and an audit-trail package ready for inspection.

    2. 2. Fractional AI governance lead

      Ongoing oversight of the validation program as new AI use cases enter the pipeline, plus regular reporting to quality and regulatory affairs leadership.

    3. 3. Specialized advisory

      Targeted review of a single AI system's validation package, or a second opinion ahead of an FDA inspection or submission.

    engagement

    How engagements are scoped and priced

    Every engagement is scoped and priced after a short discovery call.

    Straight answers

    Frequently asked questions about Part 11 Compliance for AI Systems: What the Rule Requires

    What is 21 CFR Part 11?

    21 CFR Part 11 is the FDA regulation setting the criteria under which electronic records and electronic signatures are considered trustworthy and equivalent to paper records and handwritten signatures, for records created or submitted under FDA requirements.

    Does 21 CFR Part 11 apply to AI models used in drug development?

    Yes, if the AI system touches a record that supports a regulatory submission or GxP process. Part 11's validation, audit trail, and record-integrity requirements apply regardless of whether the system is deterministic software or an AI model.

    What is FDA's risk-based AI credibility assessment framework?

    Draft guidance FDA published in January 2025 proposing that the validation evidence required for an AI model scale to its context of use, the specific role it plays in a drug or biologic submission, rather than applying one validation standard to every AI system.

    How is an AI model validated if its output changes between runs?

    Through structured output sampling against a scoring rubric, documented review of a representative sample of outputs, and ongoing drift monitoring, rather than the single deterministic test script used for traditional software validation.

    What does 21 CFR Part 11 AI validation consulting cost?

    Every engagement is scoped and priced after a short discovery call.

    Does Kriv AI work with small biotech or medical device startups?

    Kriv AI's own consulting practice focuses on enterprise and regulated life sciences organizations.

    What is Part 11 compliance?

    It means meeting 21 CFR Part 11, the FDA rule on electronic records and electronic signatures. Among other things the rule covers system validation, audit trails, copies of records and signature controls (eCFR, read 7 November 2026).

    Does Part 11 require an audit trail?

    Section 11.10(e) calls for secure, computer-generated, time-stamped audit trails. FDA's 2003 scope guidance says it intends to exercise enforcement discretion on specific audit trail requirements and that predicate rules still apply, so ask your quality team which applies to your record.

    Does Kriv AI certify that a system is Part 11 compliant?

    No. Kriv AI does not certify or attest that any system is compliant. We help teams plan validation evidence for AI systems, and the compliance decision stays with the regulated company.

    Talk to the team that would do the work

    Bring your requirements to a working session with the person who'll actually deliver.

    Book a Discovery Call